Genetically engineered fusion polypeptides
have been
investigated
to introduce unique bio-functionality and improve some therapeutic
activity for anti-angiogenesis. We report herein that stimuli-responsive,
vascular endothelial growth factor receptor 1 (VEGFR1) targeting fusion
polypeptides composed of a VEGFR1 (fms-like tyrosine kinase-1 (Flt1))
antagonist, an anti-Flt1 peptide, and a thermally responsive elastin-based
polypeptide (EBP) were rationally designed at the genetic level, biosynthesized,
and purified by inverse transition cycling to develop potential anti-angiogenic
fusion polypeptides to treat neovascular diseases. A series of hydrophilic
EBPs with different block lengths were fused with an anti-Flt1 peptide,
forming anti-Flt1-EBPs, and the effect of EBP block length on their
physicochemical properties was examined. While the anti-Flt1 peptide
decreased phase-transition temperatures of anti-Flt1-EBPs, compared
with EBP blocks, anti-Flt1-EBPs were soluble under physiological conditions.
The anti-Flt1-EBPs dose dependently inhibited the binding of VEGFR1
against vascular endothelial growth factor (VEGF) as well as tube-like
network formation of human umbilical vein endothelial cells under
VEGF-triggered angiogenesis in vitro because of the specific binding
between anti-Flt1-EBPs and VEGFR1. Furthermore, the anti-Flt1-EBPs
suppressed laser-induced choroidal neovascularization in a wet age-related
macular degeneration mouse model in vivo. Our results indicate that
anti-Flt1-EBPs as VEGFR1-targeting fusion polypeptides have great
potential for efficacious anti-angiogenesis to treat retinal-, corneal-,
and choroidal neovascularization.